CDK4 and neoplasm: Given that inhibition of CDK4 activity in TNBC cell lines results in BCSC differentiation [129] and loss of self-renewal [109], blocking CDK4 activity in this and other tumor types is a sound approach and has resulted in the approval of several CDK4/6 ATP-mimetics for use in the clinic.